Bioventus Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Bioventus Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
  • Bioventus Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 29, 2024 was -$24.3M, a 608% decline year-over-year.
  • Bioventus Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 29, 2024 was -$42.6M, a 84.9% increase year-over-year.
  • Bioventus Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$155M, a 2.31% increase from 2022.
  • Bioventus Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$159M, a 978% decline from 2021.
  • Bioventus Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was $18.1M, a 1.98% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$42.6M -$24.3M -$20.9M -608% Mar 31, 2024 Jun 29, 2024 10-Q 2024-08-06
Q1 2024 -$21.7M -$5.04M +$134M +96.4% Jan 1, 2024 Mar 30, 2024 10-Q 2024-05-07
Q4 2023 -$155M -$5.7M +$70.3M +92.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 -$226M -$7.56M +$56.6M +88.2% Jul 2, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$282M -$3.44M +$3.93M +53.4% Apr 2, 2023 Jul 1, 2023 10-Q 2024-08-06
Q1 2023 -$286M -$139M -$127M -1114% Jan 1, 2023 Apr 1, 2023 10-Q 2024-05-07
Q4 2022 -$159M -$76M -$75.8M -34623% Oct 2, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 -$83.2M -$64.2M -$62.8M -4706% Jul 3, 2022 Oct 1, 2022 10-Q 2023-11-07
Q2 2022 -$20.3M -$7.37M -$3.26M -79.4% Apr 3, 2022 Jul 2, 2022 10-Q 2023-08-08
Q1 2022 -$17.1M -$11.4M -$35.2M -148% Jan 1, 2022 Apr 2, 2022 10-Q 2023-05-16
Q4 2021 $18.1M -$219K -$4.38M -105% Oct 3, 2021 Dec 31, 2021 10-K 2024-03-12
Q3 2021 $22.5M -$1.34M -$10.7M -114% Jul 4, 2021 Oct 2, 2021 10-Q 2022-11-21
Q2 2021 $33.2M -$4.11M +$1.44M +26% Apr 4, 2021 Jul 3, 2021 10-Q 2022-08-12
Q1 2021 $31.8M $23.8M +$13.3M +127% Jan 1, 2021 Apr 3, 2021 10-Q 2022-05-11
Q4 2020 $18.5M $4.16M Sep 27, 2020 Dec 31, 2020 10-K 2023-03-31
Q3 2020 $9.4M Jun 28, 2020 Sep 26, 2020 10-Q 2021-11-10
Q2 2020 -$5.55M Mar 29, 2020 Jun 27, 2020 10-Q 2021-08-11
Q1 2020 $10.5M Jan 1, 2020 Mar 28, 2020 10-Q 2021-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.